Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.

Uitdehaag JC, de Roos JA, Prinsen MB, Willemsen-Seegers N, de Vetter JR, Dylus J, van Doornmalen AM, Kooijman J, Sawa M, van Gerwen SJ, de Man J, Buijsman RC, Zaman GJ.

Mol Cancer Ther. 2016 Dec;15(12):3097-3109. Epub 2016 Sep 1.

2.

Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.

Maia AR, de Man J, Boon U, Janssen A, Song JY, Omerzu M, Sterrenburg JG, Prinsen MB, Willemsen-Seegers N, de Roos JA, van Doornmalen AM, Uitdehaag JC, Kops GJ, Jonkers J, Buijsman RC, Zaman GJ, Medema RH.

Ann Oncol. 2015 Oct;26(10):2180-92. doi: 10.1093/annonc/mdv293. Epub 2015 Jul 7.

PMID:
26153498
3.

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.

Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, Spijkers-Hagelstein JA, de Vetter JR, de Man J, Buijsman RC, Zaman GJ.

PLoS One. 2015 May 27;10(5):e0125021. doi: 10.1371/journal.pone.0125021. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0132230.

4.

High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes.

Seegers N, van Doornmalen AM, Uitdehaag JC, de Man J, Buijsman RC, Zaman GJ.

J Biomol Screen. 2014 Oct;19(9):1266-74. doi: 10.1177/1087057114536616. Epub 2014 May 27.

PMID:
24870017
5.

Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use.

Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, de Man J, Tanizawa Y, Kawase Y, Yoshino K, Buijsman RC, Zaman GJ.

PLoS One. 2014 Mar 20;9(3):e92146. doi: 10.1371/journal.pone.0092146. eCollection 2014.

6.

Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way.

Uitdehaag JC, S√ľnnen CM, van Doornmalen AM, de Rouw N, Oubrie A, Azevedo R, Ziebell M, Nickbarg E, Karstens WJ, Ruygrok S.

J Biomol Screen. 2011 Oct;16(9):1007-17. doi: 10.1177/1087057111418113. Epub 2011 Aug 26.

PMID:
21873591
7.

High-throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogeneous assay for protein kinases.

Loomans EE, van Doornmalen AM, Wat JW, Zaman GJ.

Assay Drug Dev Technol. 2003 Jun;1(3):445-53.

PMID:
15090181
8.

sLex is not responsible for the interaction of sLex-positive memory T lymphocytes with E-selectin.

Rotteveel FT, van Doornmalen AM, van Duin M.

Immunology. 1995 Sep;86(1):34-40.

9.

In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer.

Bos ES, Kuijpers WH, Meesters-Winters M, Pham DT, de Haan AS, van Doornmalen AM, Kaspersen FM, van Boeckel CA, Gougeon-Bertrand F.

Cancer Res. 1994 Jul 1;54(13):3479-86.

Supplemental Content

Loading ...
Support Center